AAIH Founding Members

AAIH is proud of its distinguished group of founding members.
For more information about each member’s technology and company overview, link on the company logo below.

Beyond Limits

Technology

Beyond Limits artificial intelligence solutions go beyond conventional AI to unlock human potential and transform business. The company brings a highly sophisticated approach to solving healthcare problems, combining conventional numerical AI techniques with advanced symbolic reasoning to provide human-like insights. Beyond Limits reduces risk and unlike “black box” approaches, the company’s proprietary cognitive AI delivers clear explanations of its cognitive reasoning in transparent, evidence-based audit trails, including risks and uncertainties. Beyond Limits empowers clinicians with the information needed to make the best care decisions for their patients.

General

Beyond Limits creates automated solutions with human-like powers of reasoning that magnify the talents and capabilities of people. The company’s proprietary solutions provide better information to reduce risk, identify opportunities, and aid human decision-making. Beyond Limits is the only AI company in the world with advanced technology proven in extreme environments from 150 million miles into space for scientific research to 15,000 feet underground for oil and gas exploration. The company’s breakthrough cognitive technology goes beyond conventional AI, blending deep learning and machine learning tools together with symbolic AIs that emulate human intuition to afford  cognitive intelligence. Visit beyond.ai

BlackThorn Therapeutics

Technology

BlackThorn integrates multidisciplinary data science and technology teams comprised of machine learning experts, neuroscientists, clinicians, software engineers and cloud technology architects to merge academic-level scientific rigor with industry-level efficiency. BlackThorn tackles terabytes of data from an ever-widening range of functional and behavioral modalities, using our proprietary, highly-scalable, cloud-based infrastructure – PathFinder™ – and the latest-generation machine learning approaches that allow us to generate valuable insights at unprecedented speed. By creating and using technological advances in artificial intelligence, neuroinformatics, quantitative behavioral assessments, and digital biomarkers, BlackThorn is re-envisioning central nervous system (CNS) therapeutics to improve the neurobehavioral health of people suffering from these disorders.

General
BlackThorn has developed a portfolio comprised of technologies and data analytic frameworks that guide the discovery and development of a pipeline of innovative central nervous system (CNS) treatments. BlackThorn uses data-driven approaches to create a unique understanding of the core underlying pathophysiology of neurobehavioral disorders and applies these insights to generate objective neurobehavioral biomarkers that support target identification, patient stratification and clinical trial design. BlackThorn has raised $100M from top-tier investors including ARCH Ventures, JJDC, Biomatics Capital, Vertex Ventures and Polaris Partners. For more information, visit www.blackthornrx.com.

The Buck Institute for Research on Aging

Technology
The Buck Institute is currently creating a new AI Center of Excellence for Aging Research. The Center is being built from the ground up through the recruitment of a team of AI scientists and professionals with a passion for the field of aging. We anticipate that AI will become an integral component of our efforts to understand the complex, decades long process known as human aging. In particular, the new Center of Excellence will mine the vast stores of data generated by proteomics to accelerate the discovery and development of new biomarkers of aging. In addition, we expect to use AI to interrogate large cohorts containing extensive patient information including genomic sequences, biological measurements, and clinical conditions.

General
Our success will ultimately change healthcare. At the Buck, we aim to end the threat of age-related diseases for this and future generations by bringing together the most capable and passionate scientists from a broad range of disciplines to identify and impede the ways in which we age. An independent, nonprofit institution, our goal is to increase human health span, or the healthy years of life. Globally recognized as the pioneer and leader in efforts to target aging, the number one risk factor serious diseases including Alzheimer’s, Parkinson’s, cancer, macular degeneration, heart disease, and diabetes, the Buck wants to help people live better longer.  Learn more at: https://buckinstitute.org

Cyclica

Technology
Cyclica is a Toronto-based biotechnology company that leverages biophysics and artificial intelligence (AI) to drive drug discovery. Cyclica’s proprietary cloud-based Ligand Express® platform de novo uncovers the polypharmacological profiles of small molecules to provide insights into target identification and mechanism of drug action, lead prioritization, and drug repurposingCyclica has expanded the value of Ligand Express® downstream to examine the impact that genetic differences have on protein structure, and hence provide insight into structural pharmacogenomics. Over the past year and half Cyclica designed, patented, and is now optimizing its Differential Drug Design (DDD) in silico technology, which is unique in that it is built to de novo design chemical entities across a panel of desirable targets and avoid undesirable anti-targets, while maintaining retrosynthetic rules and pharmacokinetic properties through an internally built ADMET-prediction technology. In all, Cyclica’s vision is to drive drug discovery by empowering scientists with an integrated cloud-based and AI-augmented platform that enhances how they design, screen, and personalize medicines.

General
Cyclica is a Toronto-based biotechnology company that leverages biophysics and artificial intelligence (AI) to drive drug discovery by empowering scientists in pharma with an integrated cloud-based and AI-augmented platform that enhances how they design, screen, and personalize medicines. Cyclica’s flagship technology, Ligand Express® augments the discovery of novel off-target drug-protein interactions through cloud computing. By understanding polypharmacology, scientists can reduce risk in early drug discovery efforts across all diseases including those that are not well studied and lacking data such as rare, orphan, or neglected diseases. In addition to Ligand Express®, Cyclica has numerous additional technologies that extend its value to the market by going upstream into de novo drug design, and downstream into structural pharmacogenomics. For more information, visit www.cyclicarx.com and follow @Cyclica on Twitter.

Envisagenics

Technology
Envisagenics uses Artificial Intelligence and High Performance Cloud Computing to analyze patients’ RNA sequencing data to develop therapeutics for treatment of cancer and neurodegenerative diseases such as breast cancer, leukemia, and ALS. Envisagenics’ proprietary drug development software platform, SpliceCore, applies machine learning models to predict disease related RNA splicing errors, which can be addressed by nucleic acid therapeutics. SpliceCore is the largest RNA splicing event database in the world, containing almost 5 million potential drug targets and biomarkers. High Performance Cloud Computing gives SpliceCore the power and scale to accelerate the discovery of cures faster than ever before. Scientists at Envisagenics use SpliceCore on a wide range of RNA therapeutic applications including antisense oligo drug design, neoantigen detection, immunotherapy optimization, and biomarker identification for patient stratification.

General
Envisagenics uses Artificial Intelligence and High Performance Cloud Computing to analyze patients’ RNA sequencing data to develop therapeutics for treatment of cancer and neurodegenerative diseases, such as breast cancer, leukemia and ALS. Scientists at Envisagenics use proprietary drug discovery software platform called SpliceCore for antisense drug design, neoantigen detection, immunotherapy optimization, and biomarker identification for patient stratification. Investors in Envisagenics include 3kVC, Breakout Labs, Dolby Family Ventures, Madrona Venture Group, M12 (Microsoft’s Venture Fund), SVangel, and NYESD. For more information, please visit www.envisagenics.com and follow @envisagenics on twitter.

Genialis

Technology
Genialis champions a novel machine-learning-based approach to data integration and predictive modeling of disease biology—Genialis Fusion. The key principle is that the more diverse sources of information we consider, the better our models recapitulate the biological complexity that dictates whether and how patients respond to cutting edge therapies. Genialis’ cloud-based software for multi-omics data management, analysis and interpretation enables highly scalable processing of data from specific patient cohorts. The Fusion platform then integrates these data with related and orthogonal data and knowledge stores from the public domain. Today, Genialis is focused on developing biomarkers to identify patients most likely to respond favorably or adversely to immunotherapy. The company works with (bio)pharma to de-risk their pipelines, and diagnostics companies to develop the next generation of tests, to ensure the right treatments find the right patients.

General
Genialis aims to realize the promise of precision medicine by guiding the development and delivery of live-saving immunotherapeutics. The company champions a novel approach to computational modeling of disease biology—Genialis Fusion—to predict confidently which patients are likely to benefit, and which to react adversely. The key principle is that the more diverse sources of information we can consider, the better our models recapitulate biological complexity. Genialis works with (bio)pharma to de-risk their pipelines, and diagnostics companies to develop the next generation of tests, to ensure the right treatments find the right patients. Genialis is backed by RedAlpine Venture Partners and First Star Ventures. For more information, please visit www.genialis.com and follow @genialis on twitter.

Insilico Medicine

Technology
Insilico Medicine, an artificial intelligence company headquartered in Rockville MD, works in applying generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for generation of novel molecular structures for diseases with known and unknown targets. Insilico partners this expertise with an end-to-end pipeline covering drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine utilizes an internal drug discovery program to target indications in oncology, dermatological disease, metabolic disease, and neurodegenerative diseases of the Central Nervous System. Insilico also aims to apply therapeutics against these indications to improve human longevity and combat degenerative effects of aging and senescence. Insilico Medicine partners with Life Extension to provide a suite of nutraceutical products developed through application of advanced bioinformatics and deep learning approaches, and hosts a consumer product called Young AI.

General
Insilico Medicine is an artificial intelligence company headquartered in Rockville, MD with R&D and management resources in China, Russia, UK, Taiwan, and Korea. The Insilico team is dedicated to extending human productivity and longevity by transforming the drug discovery and drug development process through application of an end-to-end pipeline. Insilico specializes in the development of generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning technologies. The comprehensive approach taken by Insilico has received industry recognition for both social impact and innovation, including selection by NVIDIA as a Top 5 Social Impact AI firm in 2017, identification as a Top 100 Global AI firm by CB Insights, and receipt of the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award.

minds.ai

Technology
minds.ai is an enterprise AI consultancy specializing in applying world class deep neural network expertise and full stack engineering talent to solving their customer’s problems.  The company’s Netrin Molecular Property Prediction Platform has been trained on public datasets and is intended to be customized to perform specific functions as defined by their customer engagements and available private datasets.  At the heart of Netrin is a proprietary graph convolutional neural network, which also leverages transfer learning techniques to enable higher accuracy predictions with less data than standard deep neural network architectures.

General
minds.ai is an Enterprise AI consultancy comprised of world-class engineers from the US, EU and India who were enthusiastic about working together.  Some of the company’s partners paid them the highest compliment when they referred to minds.ai as “a Boutique Google Brain.”  The company, led by CTO Tijmen Tieleman who studied with Geoffrey Hinton at University of Toronto, combines deep neural network development expertise, with enterprise-scale, parallel computing mastery, executed by veteran software developers.  Geoffrey Hinton is widely credited for bringing deep learning expertise to Google Brain.  minds.ai has not taken venture funding which allows for a unique and collaborative business model that does not compete with its partners.  All private data used in projects remains protected and private at all times.  For more information, please visit http://minds.ai

NuMedii

Technology
NuMedii leverages machine learning to identify novel drug designs and to match potential therapeutics with in vivo targets. NuMedii leverages these findings to fuel an expanding drug development pipeline. By integrating data into a unified digital map of systems biology, NuMedii’s proprietary Artificial Intelligence for Drug Discovery (AIDD) platform allows NuMedii to build biologically relevant disease models enabling end to end in-silico discovery of novel therapeutics, druggable targets, and biomarkers. The NuMedii team pairs a robust technology platform with experience in drug development to ensure relevant medical application of its discoveries. NuMedii’s predictions have been validated through both in-vitro and in-vivo studies.

General
Since its founding in 2010, NuMedii Inc., has pioneered the use of Big Data, Artificial Intelligence (AI), and systems biology to accelerate the discovery of precision therapies to address urgent and unmet medical needs. A next generation biopharma company leveraging Stanford Intellectual Property (IP), NuMedii has built a powerful technology, Artificial Intelligence for Drug Discovery (AIDD), to harness Big Data and AI enabling rapid interrogation of the connections between existing drugs and disease biology at a systems level. NuMedii is actively engaged in R&D collaborations with global pharmaceutical, biotech companies, and patient-centric research organizations to create a new and relevant product pipeline in multiple therapeutic areas including inflammation, oncology, and rare diseases. For more information, please visit www.numedii.com.

Numerate

Technology
Numerate has developed an AI-driven drug design platform, the D4 platform, that can inform and drive drug discovery programs from hit finding to IND filing.  The D4 platform is a novel ligand-based platform, which has been successfully deployed on more than 30+ discovery programs and can be used to model and follow phenotypic assay signals as well as to model many aspects of preclinical ADME and toxicity.  Numerate uses the D4 platform to drive its internal pipeline, focused on cardiovascular disease, neurodegeneration, and inflammation.  Numerate has recently started and continues to enroll companies in its Preferred Data Partnership that is pooling ADME and toxicity data from multiple companies to build more powerful models for mutual member benefit.

General

Numerate has developed an AI-driven drug design platform, the D4 platform, that can inform and drive drug discovery programs from hit finding to IND filing.  The D4 platform is a novel ligand-based platform that has been successfully deployed on more than 30+ discovery programs, and can be used to model and follow phenotypic assay signals as well as to model many aspects of preclinical ADME and toxicity.  Numerate uses the D4 platform to drive its internal pipeline focused on cardiovascular disease, neurodegeneration, and inflammation.  Numerate also engages with other pharmaceutical companies in both asset development and data/modeling focused collaborations.  For more information, visit www.numerate.com and follow @Numerate_Inc on Twitter.

Netrias

Technology
The Active Discovery EngineTM (ADE) automates discovery through the application of distributed computing technologies, Machine Learning, and Artificial Intelligence (AI). The ADETM rapidly validates complex hypotheses through cross experiment indexing, capturing all experiment results and metadata regardless of source, raw data type, proprietary processing software or output format. Scientists search across all of their integrated experimental results over time, enabling unexpected or opportunistic discoveries. By quickly validating hypotheses and integrating across all of the available data, the ADETM allows organizations to develop the required training corpuses that empower their current personnel and resources to apply Machine Learning and AI.

General

Netrias is a fast-growing Artificial Intelligence (AI) company that specializes in boosting expert’s performance with machines. Founded in 2105, the company performs work for the U.S. Department of Defense and the National Cancer Institute of the National Institutes of Health, and applies AI to more rapidly generate breakthroughs. Netrias provides data science solutions that integrate insights and technologies into existing workflows in the life sciences sector. Its proprietary platform enables scientists to leverage the full potential of integrated, modern high-throughput screening outputs, and automates processing and analysis pipelines. Netrias offers a cross-experiment and cross-data type, expressive, life science data model and query language that accelerates the discovery cycle.  For more information, visit www.netrias.com.

Nuritas

Technology
Nuritas, a disruptive drug discovery company, deploys in-house proprietary AI platforms and machine learning to identify novel, patentable, peptide-based therapeutics across a range of disease areas in collaboration with industry partners. Via a fully integrated approach in-silico discoveries are additionally validated through internal wet laboratory studies conducted by a multidisciplinary team of scientists. Uniquely, Nuritas uses AI to interrogate natural and safe sources of material for new candidates, yielding putative drug backbones that have co-evolved with man. This strategy yields potential drugs with improved safety and toxicity profiles versus many small molecule counterparts restricted by parameters that often stifle new clinical trials and prevent new drugs reaching patients. Subsequent AI informed synthetic strategies yield new chemical activities with improved properties for better patient outcomes and scalability via traditional manufacturing approaches.

General
Nuritas, is a disruptive drug discovery company, deploys in-house proprietary AI platforms and machine learning to identify novel, patentable, peptide-based therapeutics across a range of disease areas in collaboration with industry partners. Via a fully integrated approach, Nuritas combines a computational approach (‘omics) with wet science to rapidly and efficiently predict and validate new drug candidates. Starting with natural & safe sources, Nuritas AI identifies inherently low toxicity and safe drug backbones for further synthetic development. This Nuritas data network is proprietary, yields unique insights, and has been validated by global leaders, with commercial launch of the first AI discovered bioactive by Nuritas development partner BASF in 2018. Founded in 2014, Nuritas has raised $30M from high profile investors. For more information, visit www.Nuritas and follow @NuritasResearch on Twitter.

OWKIN

Technology
OWKIN builds machine learning technologies to augment medical research and enable scientific discoveries. Its proprietary platform, OWKIN Socrates, uses machine learning technology to integrate biomedical images, genomics, and clinical data to create models aimed at discovering biomarkers, mechanisms of diseases, and treatment outcomes. To complement Socrates, OWKIN is pioneering federated and transfer learning technologies in healthcare to build collective intelligence from distributed data at scale while preserving privacy and security.

General
OWKIN builds machine learning technologies to augment medical research and enable scientific discoveries. OWKIN empowers researchers to turn real world patient data into predictive models. This AI platform boosts research capabilities for physicians and the pharmaceutical industry, improving patient treatment, drug discovery, and development. OWKIN is pioneering federated and transfer learning technologies in healthcare to build collective intelligence from distributed data at scale while preserving privacy and security. OWKIN partners with leading institutions in Europe and the US and has raised $18M from top-tier investors including GV, Otium Ventures, Cathay Innovation, and NJF Capital. For more information, visit www.owkin.com and follow @OWKINscience on Twitter.

Recursion

Technology

Recursion combines experimental biology with artificial intelligence in a parallel system to quickly and efficiently identify treatments for any disease that can be modeled at the cellular level. From massive amounts of data generated through high content imaging applications, the Recursion platform captures high-dimensional representations of thousands of disease relevant biological states and the activity of therapeutics on these states. Using this “phenomics” data, Recursion creates dynamic and informative models to discover new medicines in therapeutic programs including rare diseases, inflammation, and infectious diseases. Recursion’s vision is to leverage technology to build a robust and reliable map of human cellular biology to enable a radical shift in the pace and scale at which new treatments can be delivered to patients.

General

Recursion combines experimental biology with artificial intelligence in a massive parallel system to quickly and efficiently identify treatments for any disease that can be modeled at the cellular level. In just a few years, the company has established therapeutic programs in rare diseases, inflammation, and infectious diseases. Recursion’s vision is to leverage technology to build a robust and reliable map of human cellular biology to enable a radical shift in the pace and scale at which new treatments can be delivered to patients. Learn more at recursionpharma.com and on Twitter at @RecursionPharma.

 

University of Pittsburgh

Technology
The University of Pittsburgh looks to apply the Defense Advanced Research Projects Agency (DARPA) initiated project, Big Mechanism, to systems biology, which requires not only identification of associations between genomic or proteomic expression and phenotypes, but also necessitates the development of molecular pathway models that could be simulated to test hypotheses about drug/protein interactions. In addition, natural language processing and text mining technologies are adapted to the task of reading journal articles to aggregate the small number of causal assertions and translate them into formal representations for assembly into molecular signaling models for use in predictive applications for identifying possible drug targets. From its inception Big Mechanism has focused on causal mechanisms, in sharp contrast to Big Data which focuses on statistical association. This AI-based approach, the goal of which was to develop technology to help humans build causal, mechanistic models of highly complicated systems, such as RAS-driven cancer is used at the University to address many other medical challenges, including several prominent neurodegenerative diseases such as Alzheimer’s. 

General
The University of Pittsburgh is driving AI-enabled human-machine modeling of complicated systems.  The institution is interested in human cognition and how AI can be used to model and manage large complicated systems leading to the discovery of new knowledge. The University’s interest in natural language processing and data mining is supplemented by Bayesian modeling and machine learning methods to interrogate health care data sets particularly for medical decision support. The University’s informatics use cases include the collection of surveillance data for algorithm validation in conjunction with novel data generation for disease-outbreak detection and diagnosis, automated tutoring of medical trainees, gaming in medical and public health education, and discovery of molecular disease biomarkers. Pittsburgh employs teams of physicians, nurses, medical specialists, biologists, and computer scientist to impact public good through AI driven research efforts translated into real world public health practice.

Adjuvant Partners

General
Adjuvant Partners is a boutique advisory firm headquartered in Baltimore Maryland. The Adjuvant team specializes in business development and strategic alliance consulting for advanced technology industries, including companies engaged in cell therapy, gene therapy, tissue engineering, in-silico drug design, and ML healthcare applications. In addition to advisory work, Adjuvant Partners and its principals have long experience in assembling, launching, and growing successful industry alliance organizations, including the Biotechnology Innovation Organization (BIO), the Alliance for Regenerative Medicine (ARM), the Regenerative Medicine Standards Coordinating Body, and the ARM Foundation for Cell and Gene Medicine. Both BIO and ARM have had tremendous impact on supporting long term growth and development of the biotechnology industry through activities in education, capital formation, and regulatory & policy advocacy. Adjuvant Partners is excited to bring this same experience, vision, and energy to the AAIH to ensure successful integration of AI products into the healthcare landscape. More more information please visit the website:  https://adjuvant.com